From Open Medicine

1. Calgary researchers show that ~64 percent of Canadians have access to PCI, a life-saving heart attack procedure. http://tinyurl.com/yhqop3h
   about 2 months ago from web
    
2. What should Canadian policymakers take away from a new study on access to a life-saving heart attack treatment? http://tinyurl.com/yzbr2vn
   about 2 months ago from web
    
3. Congrats to the 3 members of Open Med's editorial family who are finalists for the BMJ Group Award for Lifetime Achievement! Vote at bmj.com
   about 2 months ago from web
    
4. Open Med's editors weigh in on ghost writing in med journals with a new ghost and guest authorship policy: http://tinyurl.com/yd8bpoc
   about 2 months ago from web
    
5. Congrats to the 3 members of Open Medicine's Ed Team and Ed Board who are finalists for the BMJ Lifetime Achievement Award! Vote at bmj.com
   about 3 months ago from web
    
6. New research: How effective are evidence-based medicine short courses, and what teaching strategies work best? http://tinyurl.com/yhysh7j
   about 3 months ago from web

Court Decides that Human Genes Cannot Be Patented

Center for Genetics and Society Calls Ruling a Victory for Patients, Consumers and Responsible Research

Contact:
Jesse Reynolds, 1-510-625-0819 x308, jreynolds [AT]geneticsandsociety[DOT]org
Marcy Darnovsky, 1-510-625-0819 x305, mdarnovsky [AT]geneticsandsociety[DOT]org

The Center for Genetics and Society, a policy research and advocacy group, welcomed yesterday’s District Court decision invalidating patents on genes associated with breast and ovarian cancer, which ruled that human genes cannot be patented because they are products of nature. This and related arguments were central to the lawsuit filed in May 2009 by the American Civil Liberties Union and the Public Patent Foundation. In support of the suit, the Center for Genetics and Society filed a “friend of the court” brief, together with the Pro-Choice Alliance for Responsible Research, Generations Ahead, the National Women’s Health Network, and Asian Communities for Reproductive Justice.

“Overturning these patents will help patients get better health care at lower costs. It removes an unnecessary and illegitimate obstacle to both medical treatment and medical research,” said Center for Genetics and Society policy analyst Jesse Reynolds.

In the lawsuit, Breast Cancer Action, Our Bodies Ourselves, individual women and breast cancer patients, genetic counselors, four scientific organizations representing more than 150,000 researchers and laboratory professionals, and individual researchers challenge patents held by Myriad Genetics and the University of Utah Research Foundation that give the biotech company exclusive control of two genes associated with an increased risk of breast and ovarian cancer, all variations of these genes, and a monopoly over tests to detect them. It represents the first time US courts have ruled on a case on human gene patents.
Myriad Genetics is expected to appeal yesterday’s decision, and many observers believe it will end up in the Supreme Court. If upheld, its implications could be far-reaching. About twenty percent of human genes have already been patented.

“Genetic research is becoming more important to the practice of medicine, and we urgently need public policies to ensure that it is responsibly conducted and that its benefits are widely accessible,” said Marcy Darnovsky, Center for Genetics and Society Associate Executive Director.

For more information:
• The amicus brief of the Center for Genetics and Society et al [PDF]
• “The Battle to Patent Your Genes: The Meaning of the Myriad Case” by Marcy Darnovsky & Jesse Reynolds, The American Interest, Sept-Oct 2009
The Center for Genetics and Society is a non-profit public affairs and policy advocacy organization working to encourage responsible uses and effective societal governance of human genetic and reproductive biotechnologies.

Agfa HealthCare contributes to innovation in diagnosis of Alzheimer Disease

Agfa HealthCare Institute partners with the Centre de recherche Université Laval Robert-Giffard to develop new technology for diagnosis of Alzheimer’s – a Canadian first

Quebec, QC – March 16, 2010 - Agfa HealthCare, a leading provider of diagnostic imaging and healthcare IT solutions, announces today that it has launched a new initiative to help improve the diagnosis of Alzheimer’s disease, in partnership with the Canadian Minister of Economic Development, Innovation and Export Trade, the Centre de recherche Université Laval Robert-Giffard and the Société de valorisation des applications de la recherche (SOVAR).  Agfa HealthCare will contribute to the development of a prototype IT solution under the Agfa HealthCare Institute – a new initiative leveraging collaborative partnerships to help facilitate innovation in the healthcare technology space.

The Alzheimer’s project* will focus on the development of a prototype that will combine a patient’s clinical information with the image features from the patient’s magnetic resonance imaging (MRI). The results will provide physicians with all of the information they need to make a faster and more accurate diagnosis of the disease. Not only will the prototype help support the diagnosis of Alzheimer’s, but it will also help physicians predict its progression and ultimately improve treatment outcomes for patients. This project, which will be underway over the next two years, is the first of its kind in Canada and the ultimate goal is to commercialize the technology developed through the research in healthcare institutions across the country.  

“Agfa HealthCare’s support is extremely important to achieving our goal of developing a functional prototype to help with the diagnosis of Alzheimer’s disease,” said Dr. Simon Duchesne, Principle Investigator of this project at the Centre de recherche Université Laval Robert-Giffard (CRULRG). “Through this joint project, we are developing innovative technology that will help improve the delivery of chronic care in Canada.”

“Research in the healthcare field represents an important niche at Université Laval,” said Edwin Bourget, Vice-President for Research and Innovation, Université Laval. “Most of the research centres are implemented in hospitals affiliated with Université Laval, among which, the Institut universitaire en santé mentale de Québec plays a major and determining role for mental health treatment, including Alzheimer’s disease, which is affecting so many Canadians today.”

For Agfa HealthCare, this Alzheimer’s project is about connecting the right people with the right information – and in order to do this, strategic partnerships are the key. The project falls under the Agfa HealthCare Institute, which was created to be a catalyst of innovations in Canada’s Health Informatics industry by facilitating close collaboration between government, the healthcare industry and universities across Canada to provide a fully integrated healthcare IT network across the continuum of care.

“Agfa HealthCare is excited to be a part of the Alzheimer’s initiative in partnership with the Université de Laval and the Minister of Economic Development, Innovation and Export Trade. With Alzheimer’s disease affecting so many Canadians, it is so important for us to contribute to the development of new techniques to help in the diagnosis and treatment of this disease,” said Dave Wilson, Vice President, Agfa HealthCare in Canada. “Through our expertise in the healthcare IT space and our strategic partnerships with institutions such as the University of Laval, we are opening up doors to new ways of improving the delivery of patient care in Canada.”

CHIME Issues Comments on Interim Final Rule on Standards, Certification

ANN ARBOR, MI, March 15, 2010 – The College of Healthcare Information Management Executives (CHIME) has released the comments it will file today with the Office of the National Coordinator for Health Information Technology regarding the initial set of standards, implementation specifications and certification criteria for electronic health record technology.

The proposed regulations, issued as an interim final rule by ONC, were unveiled on December 30, 2009, and responses are due back to the government by March 15.

Previously, on February 26, CHIME filed its comments with the Centers for Medicare & Medicaid Services regarding the EHR Incentive Program. CHIME’s ONC letter closely parallels its comments to CMS. The Ann Arbor, Mich.-based organization has 1,400 members representing chief information officers and other top information technology executives at many of the nation’s largest hospitals.

In its comments today on the interim final rule, CHIME emphasized the importance of certification for supporting providers’ efforts to achieve meaningful use, saying it gives “healthcare providers a degree of assurance that the products they purchase will perform as promised…certification is meant to support providers, not pose an additional burden.”

CHIME’s comments place the lion’s share of responsibility on vendors that develop IT products, which it says builds on past experience in the healthcare IT space. The organization also urges ONC to provide more lead time as it creates future certification criteria, so as to provide more time for providers to implement new and upgraded systems in the future.

Previously, in its comments to CMS on meaningful use regulations, CHIME had requested that a “grandfathering provision” be implemented to grant certification to products that have already been certified by the Certification Commission for Health Information Technology.

CHIME noted that further clarification is needed in ONC’s interim final rule, particularly in describing how certification will apply to organizations that use multiple clinical systems as components to an overall electronic health record system. CHIME supports wording in the rule that requires only certification of individual EHR modules.
______________________________________________________________________________________
College of Healthcare Information Management Executives
3300 Washtenaw Ave, Suite 225 ·
Ann Arbor, MI 48104
Phone: (734) 665-0000
Fax: (734) 665-4922
staff@cio-chime.org · www.cio-chime.org
______________________________________________________________________________________
CHIME’s comments ask ONC to support a single standard for patient summary records; the current interim rule allows use of either the Health Level Seven (HL7) Clinical Document Architecture (CDA) Release 2 (R2) Level 2 Continuity of Care Document (CCD) or the ASTM Continuity of Care Record (CCR) to electronically exchange a patient summary record.

“CHIME disagrees with this approach and believes that the sharing of health information across providers is best facilitated with adoption of a single standard for patient summary records,” the comment letter states. “CHIME believes that the healthcare field is ready to transition to a single standard for patient summary records, and such a move will facilitate interoperability in a more timely fashion.” The organization believes the HL7 CDA CCD is more robust and easier to read.

Medication reconciliation requirements in the interim rule need to be adjusted so that providers can meet the requirement if clinical systems can “display simultaneously two or more medication lists and provide tools for the clinician to perform medication reconciliation and create a single medication list.”

For reporting quality data, CHIME advises against using the CMS Physician Quality Reporting Initiative (PQRI) 2008 Registry XML Specification, and the related implementation specifications, the PQRI Measure Specifications Manual for Claims and Registry. Instead, it suggests the continued development of quality data reporting standards, which are in process by HL7.

CHIME also seeks a standards-based approach for submitting data to public health agencies.  Current proposals for submitting data provide wide latitude to agencies for determining the format in which they want to receive data.

In addition, CHIME comments on privacy and security standards included in the interim rule, particularly in areas of encryption and decryption of data, verification of data to ensure it hasn’t been altered in transit, and cross-enterprise authentication.

CHIME advises against placing too many requirements on data transmission within an organization. “Encryption of data in EHR databases and transactional systems would slow operation of the software, thus hindering adoption of EHRs by staff and physicians,” its comments state. “We ask that ONC and CMS carefully consider the risk vs. cost and performance issues during deliberations on this requirement.”

The letter to ONC from CHIME also included its previous comments on the proposed meaningful use regulations as an attachment.

Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study

New Zealand researchers double collaboration with Spain and Norway

PHILADELPHIA and LONDON, March 9 /CNW/ -- A study from Thomson Reuters released today shows broadening international collaboration in the research of Australia and, to a lesser degree, New Zealand, over the past 10 years. The United States continues to be the biggest contributor to Australian and New Zealand publications, but of special interest is a sizable increase of Australia's collaboration with China.

The study, Global Research Report: Australia and New Zealand, found that collaboration within the Asia Pacific region is notably changing. Though collaboration with Australia among some Asia Pacific nations (such as New Zealand, India, and Singapore) increased, and collaboration with China doubled (rising from 2.3 percent to 4.4 percent of all Australian outputs), collaboration with Japan remained unchanged. Likewise, Japan's rank as a contributor of co-authored papers with New Zealand fell from sixth to eighth. 

"Researchers in Australia and New Zealand have been increasing their share of publications co-authored with international colleagues," said Jonathan Adams, director of research evaluation at Thomson Reuters. "We've seen a shift in geographic focus of these collaborations. While such countries as Russia and South Africa decrease in importance, there are increases in collaboration with Spain and Switzerland, and more importantly, with China and India."

    Other key findings include:

    --  Australia's share of world research publication output has grown

        steadily from 2.85 percent in 1999 to 3.18 percent in 2008.

    --  In the same period, the volume of Australian publications has risen

        annually by an average of 5 percent -- a growth rate higher than that

        of world publication averages.

    --  Computer science, materials science, environment/ecology, and clinical

        medicine are subject areas where Australia has increased its outputs,

        consistent with its national research priorities.

    --  Subject areas that have grown in the volume of outputs in New Zealand

        are computer sciences, biology and biochemistry, immunology, and

        neurosciences and behavior, consistent with the country's government

        research, science and technology agenda.

The study is part of the Global Research Report series from Thomson Reuters that illustrates the changing landscape and dynamics of scientific research around the world and draws on data found in Web of Science(SM), available on the Thomson Reuters Web of Knowledge(SM), platform -- the world's largest citation environment of the highest quality scholarly literature.

For more information, please visit http://researchanalytics.thomsonreuters.com/grr/.

New studies showPCA3 prostate cancer marker can help guide repeat prostate biopsy decisions and predict risk of aggressive cancer

More than 2,400 men tested in largest worldwide studies to date.

QUEBEC CITY, March 8 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe (NASDAQ: GPRO), was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer. The studies were presented last week at the American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO GU) in San Francisco. 

"This four-year multicenter worldwide study is the largest to date performed on DiagnoCure's PCA3 marker. It shows that the test can be useful in managing patients suspected of having prostate cancer. For doctors and patients struggling with the dilemma of the traditional PSA test that has a well-known low specificity, the PCA3 test, with a specificity of up to 80% (depending on the cut-off), can offer a more reliable answer. These results indicate that the PCA3 test can help reduce unnecessary prostate biopsies and help identify patients that have a more aggressive cancer, representing a step forward in personalized patient care," said Dr Yves Fradet, co-founder and President of DiagnoCure. 

In the studies presented at the ASCO GU meeting, PCA3 was used to test urine samples from men enrolled in the REDUCE trial of GlaxoSmithKline's drug dutasteride. PCA3 testing was done on urine samples from 1,140 men in the placebo arm of the REDUCE trial, and from 1,308 men treated with dutasteride. All men underwent prostate biopsies two and four years after enrollment in the study. 

The first PCA3 study presented at the meeting originated from the placebo arm of the REDUCE trial. This study, which was highlighted in ASCO's official press program, showed that PCA3 scores were significantly correlated with a positive prostate biopsy result, and that men who had higher PCA3 scores were more likely to have prostate cancer. Specifically, cancer was diagnosed in only 6% of men with very low PCA3 scores, but in 57% of men with very high PCA3 scores. 

PCA3 scores also correlated with cancer aggressiveness (as defined by the Gleason Score): median PCA3 scores were higher in men with high-grade cancers than in those with low-grade cancers. Finally, the PCA3 test also predicted the likelihood of a positive prostate biopsy performed two years after the test. 

The second PCA3 study originated from the patients treated with dutasteride in the REDUCE trial. This study demonstrated that PCA3 also can be used to predict prostate biopsy outcomes in men taking dutasteride. It confirmed earlier research that showed PCA3 outperforms serum PSA testing for prostate cancer detection, and improves diagnostic accuracy when combined with serum PSA testing and other clinical information.

About DiagnoCure 

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. A major study published in the February 18, 2009, edition of the Journal of the American Medical Association demonstrated that GCC, to which DiagnoCure owns exclusive worldwide diagnostic rights, is the strongest independent predictor of colorectal cancer recurrence. More clinical studies are underway to confirm the clinical utility of the Previstage(TM) GCC test. The Company has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(R) PCA3 in vitro assay, and in Canada. A clinical study aimed at securing FDA approval for the commercialization of PROGENSA(R) PCA3 test in the U.S. is underway. For more information, visit www.diagnocure.com.

Proposed Rule for the Establishment of Certification Programs for Health Information Technology

A Message from Dr. David Blumenthal, National Coordinator for Health Information Technology

March 2, 2010

Today the Secretary of the Department of Health and Human Services (HHS) released a notice of proposed rulemaking (NPRM) outlining the proposed approach for establishing a certification program to test and certify electronic health records (EHRs). The HITECH Act mandates the development of a certification program which will give purchasers and users of EHR technology assurances that the technology and products have the necessary functionality and security to help meet meaningful use criteria. While we are making significant strides toward modernizing our health care system, these efforts will only succeed if providers and patients are confident that their health information systems are safe and functional.

The proposed rule incorporates two phases of development for the certification program to ensure that eligible professionals and eligible hospitals are able to adopt and implement Certified EHR Technology in time to qualify for meaningful use incentive payments. The rulemaking process will take time, so this phased approach provides a bridge  to detailed guidelines to support an ongoing program of testing and certification of health IT.

The first proposed program creates a temporary certification process under which the National Coordinator would authorize organizations to assume many of the responsibilities that will eventually be fulfilled under the permanent certification program. For the permanent certification program, the rule proposes transitioning much of the responsibility for testing and certification to organizations in the private sector.

Publication of the proposed rule on the Establishment of Certification Programs for Health Information Technology is an important first step in bringing structure and cohesion to the evaluation of EHRs, EHR modules, and potentially other types of health IT.  The programs will help support end users of certified products, and ultimately serve the interests of each patient by ensuring that their information is securely managed and available where and when it is needed.

Your input is essential to bringing this important process to fruition.  We encourage your participation in the open public comment period. 

Additional information on both of these programs and how you can comment can be found through the HHS news release issued today and at the http://HealthIT.HHS.Gov website.

The vision of the HITECH Act is unfolding rapidly, and all of us at ONC look forward to continuing to work with you to achieve the meaningful use of EHRs.

Sincerely,

David Blumenthal, M.D., M.P.P.
National Coordinator for Health Information Technology
U.S. Department of Health & Human Services

OTN offering expertise, services and solutions to organizations and healthcare jurisdictions around the world

[Another Great Canadian Success Story]

TORONTO, Feb. 26 /CNW/ - As one of the world's largest and most active telemedicine networks, the Ontario Telemedicine Network (OTN) will faciliate more than 100,000 clinical encounters and distance education opportunities for more than 300,000 people across nearly one thousand sites this year. Secure, reliable and responsive, OTN enables improved access to a variety of clinical programs and services for patients and educational opportunities for health care providers.

OTN's continued growth and success has resulted in global requests for its expertise and it has established a division to facilitate the efforts of other jurisdictions to develop their own telemedicine programs and services.

"OTN is now able to offer our expertise, services and solutions to organizations and healthcare jurisdictions around the world," says OTN CEO Dr. Ed Brown. "Using the skills, processes, technologies and services pioneered by OTN in Ontario since 1993, OTN can work with interested health care organizations and jurisdictions around the world to help them deliver a world-class Telemedicine service."

OTN offers a complete and comprehensive range of telemedicine solutions and services. From those just getting started to those considering scaling up an existing telemedicine operation to the next level, OTN can now offer healthcare jurisdictions around the world a comprehensive telemedicine offering so that they are able to focus on patient care.

In addition, OTN continues to respond to its goal of increased adoption of telemedicine by enabling a more efficient, inexpensive way to integrate telemedicine into a health care provider's practice. OTN has integrated Polycom's PC-based Converged Management Application (CMA) with OTN's sophisticated telemedicine tools and practices. "OTN has been a true innovator and leader in the telehealth market for a number of years," said Dr. Deborah Jeffries, director of Healthcare Markets at Polycom. "We're honored to work with the team at OTN, and we're excited to demonstrate our combined solutions at HIMSS10."

Demonstrations will be featured at both the OTN booth No.6210 and the Polycom booth No.6201.

For further information: Rhona Lahey, Government and Media Relations, (613) 867-9498, rlahey@otn.ca

Gartner enters into Agreement to Acquire AMR Research, Inc.

STAMFORD, Conn., December 1, 2009 —    Gartner, Inc. (NYSE: IT), the leading provider of research and analysis on the global information technology industry, today announced that it has agreed to acquire AMR Research, Inc. for approximately $64 million in cash, subject to certain closing adjustments. With projected full year 2009 revenues of approximately $40 million, AMR Research is a leading research and advisory services firm serving supply chain management and IT professionals. The firm is recognized for its research focused on the intersection of business processes and technology for the supply chain professional.

The acquisition of AMR Research is expected to expand Gartner's suite of research offerings and also complement its consulting and events businesses. Moreover, the addition of AMR Research’s experienced sales team should enhance Gartner's ability to further penetrate the vast market opportunity for syndicated research. The combination is also expected to drive operational efficiencies and cost savings.

Gene Hall, Gartner's chief executive officer, said, "AMR Research is an excellent strategic fit for Gartner. The firm is the market leader for research related to supply chain management, which is inextricably linked to IT and has become a central and growing issue for many organizations. We expect the acquisition to give us immediate presence in this market and the ability to generate substantial synergies by selling AMR Research products to Gartner clients and Gartner products to AMR Research clients. The addition of AMR Research’s team of approximately 40 research analysts and 45 sales executives should enable us to offer expanded resources to our clients and increase our opportunities for growth."

The Advisory Board Company and HIMSS Analytics to Collaborate to Solve Health Care IT Challenges

New Suite of Services will Combine HIMSS Analytics’ Deep IT Knowledge and Database with the Advisory Board’s Best Practice Operational and Clinical Expertise

WASHINGTON, D.C. -- (March 1, 2010) – The Advisory Board Company and HIMSS Analytics™ LLC are collaborating to provide a new level of business-oriented information technology (IT) research to health care executives and IT leaders.  Through this affiliation, data from the HIMSS Analytics™ Database will be provided to The Advisory Board Company as the foundation for new and expanded services and projects.

Both organizations recognize that hospitals and health systems now face mounting pressures to reach the full potential of their IT systems and drive broad performance improvement for their institutions. This initiative will help IT professionals meet these challenges by pairing HIMSS Analytics’ deep IT knowledge and rich database with the Advisory Board’s best practice operational and clinical expertise. David E. Garets, President and Chief Executive Officer of HIMSS Analytics, and Mike Davis, Executive Vice President of HIMSS Analytics, will leave HIMSS Analytics at the end of March to join The Advisory Board Company and lead the effort.

“We are thrilled to tap into the deep data resources of HIMSS Analytics,” said Robert Musslewhite, Chief Executive Officer of The Advisory Board Company. “CIOs across our 2,600+ hospital and health system members face key challenges in change management, performance improvement, and transparency.  Together with HIMSS Analytics data, we will provide CIOs and other executives with a new level of support as they work to implement key information systems and drive real gains for their institutions.”

With the proposed rules for meaningful use for the electronic health record now under review, internal and market forces are converging to require more integrated clinical models in order to deliver higher-value health care.  In this context, innovative workflow processes and clinical practice, built upon sound IT choices and strong implementation execution, are critical to future hospital and health system success.  The Advisory Board Company, together with HIMSS Analytics data, will enable hospital and health systems to improve technology adoption by physicians and other important stakeholders, leverage the technology to impact care delivery, and drive continued value from IT investments.

“The addition of HIMSS Analytics’ data on IT processes and environments, costs and management metrics, and purchasing decisions will greatly enrich the work that we do with our member CIOs,” said Musslewhite. “This initiative also provides an outstanding opportunity for us to serve the broader executive suite in a more in-depth way on technology issues that are strategically important to the future success of their institutions.  We are particularly excited about the IT knowledge and expertise that Dave and Mike bring to the Advisory Board.  This is a winning combination, and I am confident that it will create tremendous value for our members and for all the additional members who come on board to take advantage of this work.”

“Successful IT choices require deep expertise on the environment in which the system will operate,” said H. Stephen Lieber, President and CEO of Healthcare Information Management Systems Society (HIMSS). “The Advisory Board’s nuanced understanding of best practices in the clinical and operational setting of hospitals provides a critical perspective to IT leaders.  For our part, HIMSS Analytics is excited about this new chapter in our work.  Together, HIMSS Analytics and the Advisory Board will support IT users, business users, and clinical users across the full project planning and implementation cycle to yield successful IT projects that drive real returns.  We look forward to a long and fruitful relationship.”

For more information or to register for The Advisory Board Company’s Web conference on the new suite of services for health care IT leaders, visit www.advisory.com/public/cio.

About The Advisory Board Company

The Advisory Board Company provides best practices research, analysis, executive education and leadership development, software tools, and installation support services primarily to the health care industry, focusing on business strategy, operations, and general management issues. The Company provides best practices and research through discrete programs to a membership of approximately 2,800 organizations, including leading hospitals, health systems, pharmaceutical and biotech companies, health care insurers, medical device companies, colleges, universities, and other education institutions. Members of each program are typically charged a fixed annual fee and have access to an integrated set of services that may include best practice research studies, executive education seminars, customized research briefs, web-based access to the program’s content database, and software tools.

About HIMSS Analytics

HIMSS Analytics is a wholly owned not-for-profit subsidiary of the Healthcare Information and Management Systems Society (HIMSS). HIMSS Analytics collects and analyzes healthcare information related to IT processes and environments, products, IS department composition and costs, IS department management metrics, healthcare trends and purchase-related decisions. HIMSS Analytics delivers high quality products, services and analytical expertise to healthcare delivery organizations, healthcare IT companies, state governments, financial companies, pharmaceutical companies, and consulting firms. Visit www.himssanalytics.org for more information.

A Longwoods Publishing working relationship with HIMSS Analytics will survive this collaboration.